WaveMan
WaveMan · Company
ARCT · Arcturus Therapeutics Holdings Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ARCT Arcturus Therapeutics (ARCT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001768224
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
75
13F, latest reported quarter

Arcturus Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Arcturus Therapeutics Holdings Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
SASSINE ANDY
Chief Financial Officer
BUY
2025-08-20 SECtraded 2025-08-15
1,238
$20.5K
-35.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 12, 2024.
  • The trade is 0.6% of the 221,764 shares held after it.
  • No other insider bought within 30 days.
  • 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer SASSINE ANDY bought about $20.5K of ARCT on Aug 15, 2025, the largest insider purchase at the company since 2022; 75 funds added in the latest 13F quarter.
Chivukula Pad
Chief Scientific Officer & COO
SELL
2024-10-16 SECtraded 2024-10-15
12,000
$249.1K
-45.5%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Jun 5, 2024.
  • The trade is 2.8% of the 435,334 shares held after it.
  • No other insider sold within 30 days.
  • 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer & COO Chivukula Pad sold about $249.1K of ARCT on Oct 15, 2024; 75 funds added in the latest 13F quarter.
SASSINE ANDY
Chief Financial Officer
SELL
2024-06-14 SECtraded 2024-06-12
50,000
$1.6M
-60.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 22.7% of the 220,526 shares held after it.
  • 1 other insider sold within 30 days.
  • 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer SASSINE ANDY sold about $1.6M of ARCT on Jun 12, 2024, the largest insider sale at the company since 2021; 1 other insider sold within 30 days and 75 funds added in the latest 13F quarter.
Chivukula Pad
Chief Scientific Officer & COO
SELL
2024-06-07 SECtraded 2024-06-05
114
$5.1K
-64.8%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Jun 3, 2024.
  • The trade is 0.0% of the 447,334 shares held after it.
  • 1 other insider sold within 30 days.
  • 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer & COO Chivukula Pad sold about $5.1K of ARCT on Jun 5, 2024; 1 other insider sold within 30 days and 75 funds added in the latest 13F quarter.
Chivukula Pad
Chief Scientific Officer & COO
SELL
2024-06-04 SECtraded 2024-06-03
26,000
$1.0M
-74.7%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on Mar 25, 2024.
  • The trade is 5.8% of the 447,448 shares held after it.
  • 1 other insider sold within 30 days.
  • 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer & COO Chivukula Pad sold about $1.0M of ARCT on Jun 3, 2024, the largest insider sale at the company since 2021; 1 other insider sold within 30 days and 75 funds added in the latest 13F quarter.
32 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 27 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
75 funds bought in last quarter
more than 58% of Pharma & Biotech
Revenue
-46.1% year over year
below 79% of Pharma & Biotech
Margin
-80.2% net margin
below 55% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
20.9% of the float short (float per yahoo 2026-10-27) · 8.4 days to cover · settled 2026-10-15
more than 93% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ARCT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-6.4%12M
-54%-22%+9%+41%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ARCT: institutional holders (13F)

13F holdings, latest reported quarter
FEDERATED HERMES, INC.
3,303,640 sh
$22.2M
ARK Investment Management LLC
2,901,635 sh
$19.5M
BlackRock, Inc.
2,614,012 sh
$17.6M
Sumitomo Mitsui Trust Group, Inc.
1,963,123 sh
$13.2M
Amova Asset Management Americas, Inc.
1,960,458 sh
$13.1M

Congress trades in ARCT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ARCT planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ARCT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ARK Genomic Revolution ETF
$15.8M position · as of 2026-07-31
1.0%
Jacob Discovery Fund
$105.9K position · as of 2026-05-31
0.7%
Federated Hermes Kaufmann Fund II
$298.6K position · as of 2026-06-30
0.3%
Federated Hermes Kaufmann Small Cap Fund
$6.8M position · as of 2026-07-31
0.2%
Federated Hermes Kaufmann Fund
$11.3M position · as of 2026-07-31
0.2%
AXS Green Alpha ETF
$104.9K position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 75 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ARCT financials

Revenue growth
-46.1%
XBRL, annual
Net margin
-80.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$29.4M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-317.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$72.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.44x
long-term 2025-03-31 (15 months older than the period end) plus current 2022-12-31 (42 months older than the period end); equity 2026-06-30
Cash flow to debt
-0.96x
TTM operating cash flow over long-term 2025-03-31 (15 months older than the period end) plus current 2022-12-31 (42 months older than the period end)
Return on equity
-46.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-35.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-45.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$203.4M
market value at close 2026-10-27 on 2026-08-04 shares, plus long-term 2025-03-31 (15 months older than the period end) plus current 2022-12-31 (42 months older than the period end), minus cash 2026-06-30
FCF yield
-22.8%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$82.0M$152.3M$166.8M$206.0M
Operating income-$76.3M-$95.7M-$78.2M$12.2M
Net income-$65.8M-$80.9M-$29.7M$9.3M
EPS (diluted)-2.40-3.00-1.120.35
Operating cash flow-$74.3M-$59.7M-$18.1M$32.0M
Cash$230.9M$237.0M$292.0M$391.9M
SEC XBRL, fiscal years, as known on 2026-10-28

ARCT Stock Sonar score 5/7 axes

Find similar shapesCompare

ARCT ranks highest on institutional and government (58th percentile) and profitability (56th), and lowest on growth (21st), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
56
Inputs
  • Return on equity-46.3% · 56 pct, sector of 545
  • Return on assets-35.0% · 56 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-45.1% · 55 pct, sector of 576
Financial health
44
Inputs
  • Debt to equity0.44x · 34 pct, sector of 352
  • Cash flow to debt-0.96x · 53 pct, sector of 371
Growth
21
Inputs
  • Revenue growth, YoY-46.1% · 21 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
58
Inputs
  • Funds adding, latest quarter75 · 58 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
35
Inputs
  • Short interest, % of float+20.9% · 14 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+9.5% · 56 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies